# Bicara Therapeutics (BCAX) — Analyst Forecast

BCAX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/bcax/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 12 | 1 | 0 | 13 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $20.00 | $29.86 | $39.00 | 7 |

Last price $17.62 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Aug 19, 2026 | BMO Capital | Initiated Coverage | Outperform | $35.00 |
| Aug 12, 2026 | BTIG | Maintained | Buy | $39.00 |
| Aug 12, 2026 | Wells Fargo | Maintained | Equal-Weight | $23.00 |
| Aug 12, 2026 | Mizuho | Maintained | Neutral | $20.00 |
| Aug 12, 2026 | Morgan Stanley | Maintained | Overweight | $39.00 |
| Aug 12, 2026 | Wedbush | Maintained | Outperform | $33.00 |
| Aug 12, 2026 | Goldman Sachs | Maintained | Neutral | $20.00 |
| May 12, 2026 | Morgan Stanley | Maintained | Overweight | $37.00 |
| May 12, 2026 | Goldman Sachs | Maintained | Neutral | $18.00 |
| May 11, 2026 | Guggenheim | Initiated Coverage | Buy | $42.00 |
| Mar 31, 2026 | HC Wainwright & Co. | Maintained | Buy | $42.00 |
| Mar 31, 2026 | Wells Fargo | Maintained | Equal-Weight | $16.00 |
| Mar 31, 2026 | Wedbush | Maintained | Outperform | $30.00 |
| Mar 31, 2026 | Goldman Sachs | Maintained | Neutral | $16.00 |
| Mar 31, 2026 | Citizens | Maintained | Market Outperform | $31.00 |
| Mar 25, 2026 | B of A Securities | Initiated Coverage | Buy | $35.00 |
| Jan 29, 2026 | Citizens | Initiated Coverage | Market Outperform | $31.00 |
| Jan 13, 2026 | Wedbush | Maintained | Outperform | $30.00 |
| Jan 8, 2026 | BTIG | Initiated Coverage | Buy | $28.00 |
| Dec 18, 2025 | Mizuho | Initiated Coverage | Neutral | $18.00 |

## Frequently Asked Questions

### What is the price target for BCAX stock?

The average 12-month analyst price target for Bicara Therapeutics (BCAX) is $29.86, with a high estimate of $39.00 and a low of $20.00, across 7 analysts.

### Is BCAX a buy, sell, or hold?

Analysts covering Bicara Therapeutics currently average a Buy rating: 12 buy, 1 hold and 0 sell, from 13 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for BCAX?

The average price target of $29.86 implies 69.45% upside from the last price of $17.62.

### What is the latest analyst rating on BCAX?

On Aug 19, 2026, BMO Capital initiated coverage of Bicara Therapeutics at Outperform with a price target of $35.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).